674PDelpacibart zotadirsen (del-zota) increased dystrophin and improved muscle integrity markers regardless of ambulatory status in individuals with DMD44
Aravindhan Veerapandiyan(Arkansas Children's Hospital), Elizabeth Ackermann(Electronic BioSciences (United States)), Brenda Wong(Cincinnati Children's Hospital Medical Center), Jamie M. Eskuri(Gillette Children's Specialty Healthcare), Philip Kovach(Electronic BioSciences (United States)), Jürgen Herzog(Electronic BioSciences (United States)), Michael W. Morris(Columbia University), Edward C. Smith(Duke Institute for Health Innovation), Steven G. Hughes(Ionis Pharmaceuticals (United States)), Yvonne Tami(Electronic BioSciences (United States)), Yongxia Zhu(University of Electronic Science and Technology of China), H. Phan(Rare Disease Therapeutics (United States)), C. Laverty(University of California San Diego), Terry Carmack(Electronic BioSciences (United States)), K. Flanigan(Nationwide Children's Hospital), Carolina Tesi Rocha(Stanford University)
Cited by 1
Related Papers
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k
Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
|New England Journal of Medicine|2019|663
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
|New England Journal of Medicine|2015|526
Targeting APOC3 in the Familial Chylomicronemia Syndrome
|New England Journal of Medicine|2014|492
AZD9150, a next-generation antisense oligonucleotide inhibitor of <i>STAT3</i> with early evidence of clinical activity in lymphoma and lung cancer
|Science Translational Medicine|2015|438